Log in

NASDAQ:SAVACassava Sciences Stock Price, Forecast & News

$2.14
+0.03 (+1.42 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.07
Now: $2.14
$2.15
50-Day Range
$2.11
MA: $5.53
$9.64
52-Week Range
$1.03
Now: $2.14
$10.95
Volume921,919 shs
Average Volume4.82 million shs
Market Capitalization$53.03 million
P/E RatioN/A
Dividend YieldN/A
Beta3.28
Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.10 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SAVA
CUSIPN/A
CIKN/A
Phone512-501-2444

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.00 per share

Profitability

Net Income$-4,630,000.00

Miscellaneous

Employees9
Market Cap$53.03 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive SAVA News and Ratings via Email

Sign-up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter.

Cassava Sciences (NASDAQ:SAVA) Frequently Asked Questions

How has Cassava Sciences' stock been impacted by COVID-19 (Coronavirus)?

Cassava Sciences' stock was trading at $4.24 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SAVA shares have decreased by 49.5% and is now trading at $2.14. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cassava Sciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cassava Sciences.

When is Cassava Sciences' next earnings date?

Cassava Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Cassava Sciences.

How were Cassava Sciences' earnings last quarter?

Cassava Sciences Inc (NASDAQ:SAVA) released its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.05) earnings per share for the quarter. View Cassava Sciences' earnings history.

When did Cassava Sciences' stock split? How did Cassava Sciences' stock split work?

Cassava Sciences shares reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SAVA?

2 Wall Street analysts have issued 1 year target prices for Cassava Sciences' stock. Their forecasts range from $12.00 to $16.00. On average, they expect Cassava Sciences' share price to reach $14.00 in the next year. This suggests a possible upside of 554.2% from the stock's current price. View analysts' price targets for Cassava Sciences.

What are Wall Street analysts saying about Cassava Sciences stock?

Here are some recent quotes from research analysts about Cassava Sciences stock:
  • 1. According to Zacks Investment Research, "Cassava Sciences Inc. is focused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer's. Cassava Sciences Inc., formerly known as Pain Therapeutics Inc., is based in Austin, United States. " (5/9/2020)
  • 2. Maxim Group analysts commented, "Cassava announced the initiation of Phase 2b for its lead therapeutic candidate PTI-125 in mild-moderate Alzheimer’s disease (AD). The first two patients of the trial have been dosed. The Phase 2b initiation follows positive Phase 2a results (see note 9/9, LINK) in which a 100% responder rate and statistically significant reductions (p<0.001) in key AD biomarkers were noted, including an improved cerebrospinal fluid (CSF) P-tau to Aβ42 ratio (p<0.001), which has been found to correlate with cognitive deficiencies."" (9/18/2019)

Has Cassava Sciences been receiving favorable news coverage?

Press coverage about SAVA stock has trended very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cassava Sciences earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutCassava Sciences.

Who are some of Cassava Sciences' key competitors?

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), DURECT (DRRX), Bristol-Myers Squibb (BMY), Synergy Pharmaceuticals (SGYP), Baidu (BIDU), Exelixis (EXEL), Novavax (NVAX) and Opko Health (OPK).

Who are Cassava Sciences' key executives?

Cassava Sciences' management team includes the following people:
  • Mr. Remi Barbier, Founder, Chairman, CEO & Pres (Age 59)
  • Mr. Eric J. Schoen, Chief Financial Officer (Age 51)
  • Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 76)
  • Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs

What is Cassava Sciences' stock symbol?

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sphera Funds Management LTD. (2.48%), UBS Group AG (1.21%), Ikarian Capital LLC (1.21%), Geode Capital Management LLC (0.45%), Bank of New York Mellon Corp (0.31%) and Morgan Stanley (0.25%). Company insiders that own Cassava Sciences stock include Armistice Capital Master Fund, Armistice Capital, Llc, Eric Schoen, Remi Barbier and Sanford Robertson. View institutional ownership trends for Cassava Sciences.

Which major investors are selling Cassava Sciences stock?

SAVA stock was sold by a variety of institutional investors in the last quarter, including Bleichroeder LP, Two Sigma Investments LP, Geode Capital Management LLC, and Cetera Advisor Networks LLC. View insider buying and selling activity for Cassava Sciences.

Which major investors are buying Cassava Sciences stock?

SAVA stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Ikarian Capital LLC, UBS Group AG, Morgan Stanley, Bank of New York Mellon Corp, Quinn Opportunity Partners LLC, ClariVest Asset Management LLC, and Creative Planning. Company insiders that have bought Cassava Sciences stock in the last two years include Eric Schoen, Remi Barbier, and Sanford Robertson. View insider buying and selling activity for Cassava Sciences.

How do I buy shares of Cassava Sciences?

Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cassava Sciences' stock price today?

One share of SAVA stock can currently be purchased for approximately $2.14.

How big of a company is Cassava Sciences?

Cassava Sciences has a market capitalization of $53.03 million. The company earns $-4,630,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Cassava Sciences employs 9 workers across the globe.

What is Cassava Sciences' official website?

The official website for Cassava Sciences is www.cassavasciences.com.

How can I contact Cassava Sciences?

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company can be reached via phone at 512-501-2444 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.